New hope for myeloma patients Who've run out of options
NCT ID NCT05981209
Summary
This early-stage trial is testing whether combining three existing drugs—elotuzumab, CC-92480, and dexamethasone—is safe and effective for people with multiple myeloma that has returned or stopped responding to treatment. The study involves 27 patients whose cancer has progressed despite trying at least two prior therapies, including the most advanced treatments available. Researchers aim to find the best dose and see if this combination can help control the disease when other options have failed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.